{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T11:46:06Z","timestamp":1793879166199,"version":"4.7.0"},"reference-count":33,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.euo.2026.06.006","type":"journal-article","created":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T03:35:15Z","timestamp":1782358515000},"page":"1046-1054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials"],"prefix":"10.1016","volume":"9","author":[{"given":"Pietro","family":"Scilipoti","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksander","family":"\u015alusarczyk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constance","family":"Thibault","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Piotr","family":"Doma\u0144ski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Necchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Montorsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Briganti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Moschini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra","family":"Masson-Lecomte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashish M.","family":"Kamat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evanguelos","family":"Xylinas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin","family":"Pradere","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahrokh","family":"Shariat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quoc-Dien","family":"Trinh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alison","family":"Birtle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joaquim","family":"Bellmunt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yohann","family":"Loriot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Seisen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.06.006_b0005","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1016\/j.eururo.2011.12.010","article-title":"Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer","volume":"61","author":"Rosenblatt","year":"2012","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.006_b0010","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.euf.2019.08.009","article-title":"Clinical complete response after neoadjuvant chemotherapy for muscle-invasive bladder cancer: a call for standardized assessments and definitions","volume":"6","author":"Winoker","year":"2020","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.euo.2026.06.006_b0015","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1377\/hlthaff.24.1.67","article-title":"Surrogate endpoints and FDA's accelerated approval process","volume":"24","author":"Fleming","year":"2005","journal-title":"Health Aff"},{"key":"10.1016\/j.euo.2026.06.006_b0020","unstructured":"US Food and Drug Administration. Endpoints for the development of neoadjuvant systemic therapy regimens for muscle-invasive bladder cancer. News & Events for Human Drugs; 2019. https:\/\/www.fda.gov\/drugs\/news-events-human-drugs\/fda-bcan-workshop-endpoints-development-neoadjuvant-systemic-therapy-regimens-muscle-invasive. Accessed January 30, 2026."},{"key":"10.1016\/j.euo.2026.06.006_b0025","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.06.006_b0030","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1200\/JCO.19.03114","article-title":"Event-free survival, a prostate-specific antigen-based composite end point, is not a surrogate for overall survival in men with localized prostate cancer treated with radiation","volume":"38","author":"Xie","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0035","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0040","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djv261","article-title":"The development of intermediate clinical endpoints in cancer of the prostate (ICECaP)","volume":"107","author":"ICECaP Working Group","year":"2015","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.euo.2026.06.006_b0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1177\/0962280207082719","volume":"17","author":"Lassere","year":"2008","journal-title":"Stat Methods Med Res"},{"key":"10.1016\/j.euo.2026.06.006_b0050","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1007\/s10147-012-0447-z","article-title":"Efficacies and safety of neoadjuvant gemcitabine plus carboplatin followed by immediate cystectomy in patients with muscle-invasive bladder cancer, including those unfit for cisplatin: a prospective single-arm study","volume":"18","author":"Koie","year":"2013","journal-title":"Int J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0055","doi-asserted-by":"crossref","first-page":"8.e1","DOI":"10.1016\/j.urolonc.2017.08.020","article-title":"Neoadjuvant sorafenib, gemcitabine, and cisplatin administration preceding cystectomy in patients with muscle-invasive urothelial bladder carcinoma: an open-label, single-arm, single-center, phase 2 study","volume":"36","author":"Necchi","year":"2018","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0060","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.1158\/1078-0432.CCR-22-2158","article-title":"Neoadjuvant pembrolizumab and radical cystectomy in patients with muscle-invasive urothelial bladder cancer: 3-year median follow-up update of PURE-01 trial","volume":"28","author":"Basile","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.euo.2026.06.006_b0065","first-page":"1312","article-title":"Neoadjuvant atezolizumab with gemcitabine and cisplatin in patients with muscle-invasive bladder cancer: a multicenter, single-arm","volume":"40","author":"Funt","year":"2022","journal-title":"Phase II trial. J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0070","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1016\/S1470-2045(22)00158-9","article-title":"Addition of nintedanib or placebo to neoadjuvant gemcitabine and cisplatin in locally advanced muscle-invasive bladder cancer (NEOBLADE): a double-blind, randomised, phase 2 trial","volume":"23","author":"Hussain","year":"2022","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0075","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.eururo.2023.06.014","article-title":"Long-term outcomes from a Phase 2 study of neoadjuvant chemotherapy for muscle-invasive bladder cancer (SWOG S1314; NCT02177695)","volume":"84","author":"Flaig","year":"2023","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.006_b0080","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-012045","article-title":"Avelumab-based neoadjuvant therapy in patients with muscle-invasive bladder cancer (AURA Oncodistinct-004): a phase 2 multicenter clinical trial","volume":"13","author":"Blanc","year":"2025","journal-title":"J Immunother Cancer"},{"key":"10.1016\/j.euo.2026.06.006_b0085","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1056\/NEJMoa022148","article-title":"Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer","volume":"349","author":"Grossman","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.006_b0090","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1093\/annonc\/mdu126","volume":"25","author":"Kitamura","year":"2014","journal-title":"Ann Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0095","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/S1470-2045(23)00587-9","article-title":"Perioperative dose-dense methotrexate, vinblastine, doxorubicin, and cisplatin in muscle-invasive bladder cancer (VESPER): survival endpoints at 5 years in an open-label, randomised, phase 3 study","volume":"25","author":"Pfister","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0100","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1056\/NEJMoa2408154","article-title":"Perioperative durvalumab with neoadjuvant chemotherapy in operable bladder cancer","volume":"391","author":"Powles","year":"2024","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.006_b0105","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1056\/NEJMoa2511674","article-title":"Perioperative enfortumab vedotin and pembrolizumab in bladder cancer","volume":"394","author":"Vulsteke","year":"2026","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.006_b0110","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1056\/NEJMoa2511885","article-title":"ctDNA-guided adjuvant atezolizumab in muscle-invasive bladder cancer","volume":"393","author":"Powles","year":"2025","journal-title":"N Engl J Med"},{"key":"10.1016\/j.euo.2026.06.006_b0115","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1158\/2767-9764.CRC-24-0234","article-title":"ctDNA detected after neoadjuvant therapy for HER2-positive breast cancer is associated with inferior outcomes and may inform adjuvant therapy","volume":"6","author":"Lin","year":"2026","journal-title":"Cancer Res Commun"},{"key":"10.1016\/j.euo.2026.06.006_b0120","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102377","article-title":"Prognostic implications of patients with clinically node positive bladder cancer undergoing radical cystectomy","volume":"23","author":"Scilipoti","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.06.006_b0125","doi-asserted-by":"crossref","DOI":"10.1016\/j.clgc.2025.102399","article-title":"Comparative assessment of chemotherapy followed by consolidative radical cystectomy versus chemoradiation for clinically node-positive urothelial carcinoma of the bladder","volume":"23","author":"\u015alusarczyk","year":"2025","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.euo.2026.06.006_b0130","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/j.eururo.2026.01.013","article-title":"Regional node-positive bladder cancer: therapeutic decisions based on trial results in perioperative and advanced disease settings","volume":"89","author":"Pichler","year":"2026","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.006_bib161","doi-asserted-by":"crossref","DOI":"10.6004\/jnccn.2026.7014","article-title":"Surrogacy of Intermediate Clinical Endpoints for Overall Survival in Patients With Localized Muscle-Invasive Bladder Cancer","author":"Scilipoti","year":"2026","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.euo.2026.06.006_b0135","doi-asserted-by":"crossref","first-page":"2988","DOI":"10.1200\/JCO.22.02363","volume":"41","author":"Squifflet","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0140","article-title":"Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysis","volume":"375","author":"Conforti","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.euo.2026.06.006_b0145","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.70220","article-title":"Event-free survival and complete response rate as surrogate endpoints for overall survival in high-risk non-muscle-invasive bladder cancer: a meta-analysis of bacillus Calmette-Gu\u00e9rin-naive or -remote cases","volume":"132","author":"Bhattacharya","year":"2026","journal-title":"Cancer"},{"key":"10.1016\/j.euo.2026.06.006_b0150","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.eururo.2007.08.041","article-title":"Prostate-specific antigen (PSA) as a surrogate end point for survival in prostate cancer clinical trials","volume":"53","author":"Collette","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.euo.2026.06.006_b0155","doi-asserted-by":"crossref","first-page":"3944","DOI":"10.1200\/JCO.2013.50.3201","article-title":"Prostate-specific antigen changes as surrogate for overall survival in men with metastatic castration-resistant prostate cancer treated with second-line chemotherapy","volume":"31","author":"Halabi","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.06.006_b0160","unstructured":"Galsky MD. Enfortumab vedotin plus pembrolizumab may reduce risk of recurrence for some muscle-invasive bladder cancer cases: results from the phase 3 KEYNOTE-B15 trial. Presented at: American Society of Clinical Oncology Genitourinary Cancers Symposium (ASCO GU 2026); 2026. San Francisco, CA."}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001744?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001744?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T09:33:13Z","timestamp":1793525593000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001744"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":33,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2588931126001744"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.006","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evaluating the Surrogacy of Pathological Complete Response at Radical Cystectomy in Neoadjuvant-based Muscle-invasive Bladder Cancer Trials","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.06.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}